BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37913851)

  • 1. Direct evaluation of polarity of the ligand binding pocket in retinoid X receptor using a fluorescent solvatochromic agonist.
    Miura K; Fujihara M; Watanabe M; Takamura Y; Kawasaki M; Nakano S; Kakuta H
    Bioorg Med Chem Lett; 2023 Nov; 96():129536. PubMed ID: 37913851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescent retinoid X receptor ligands for fluorescence polarization assay.
    Yamada S; Ohsawa F; Fujii S; Shinozaki R; Makishima M; Naitou H; Enomoto S; Tai A; Kakuta H
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5143-6. PubMed ID: 20667726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene.
    Dawson MI; Ye M; Cao X; Farhana L; Hu QY; Zhao Y; Xu LP; Kiselyuk A; Correa RG; Yang L; Hou T; Reed JC; Itkin-Ansari P; Levine F; Sanner MF; Fontana JA; Zhang XK
    ChemMedChem; 2009 Jul; 4(7):1106-19. PubMed ID: 19378296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343.
    Yukawa-Takamatsu K; Wang Y; Watanabe M; Takamura Y; Fujihara M; Nakamura-Nakayama M; Yamada S; Kikuzawa S; Makishima M; Kawasaki M; Ito S; Nakano S; Kakuta H
    J Med Chem; 2021 Jan; 64(1):861-870. PubMed ID: 33378197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a "Gatekeeper" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.
    Watanabe M; Fujihara M; Motoyama T; Kawasaki M; Yamada S; Takamura Y; Ito S; Makishima M; Nakano S; Kakuta H
    J Med Chem; 2021 Jan; 64(1):430-439. PubMed ID: 33356247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies.
    Pogenberg V; Guichou JF; Vivat-Hannah V; Kammerer S; Pérez E; Germain P; de Lera AR; Gronemeyer H; Royer CA; Bourguet W
    J Biol Chem; 2005 Jan; 280(2):1625-33. PubMed ID: 15528208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers.
    Vivat V; Zechel C; Wurtz JM; Bourguet W; Kagechika H; Umemiya H; Shudo K; Moras D; Gronemeyer H; Chambon P
    EMBO J; 1997 Sep; 16(18):5697-709. PubMed ID: 9312028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioligand binding assay for accurate determination of nuclear retinoid X receptors: A case of triorganotin endocrine disrupting ligands.
    Toporova L; Macejova D; Brtko J
    Toxicol Lett; 2016 Jul; 254():32-6. PubMed ID: 27153798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective allosteric ligand activation of the retinoid X receptor heterodimers of NGFI-B and Nurr1.
    Morita K; Kawana K; Sodeyama M; Shimomura I; Kagechika H; Makishima M
    Biochem Pharmacol; 2005 Dec; 71(1-2):98-107. PubMed ID: 16288995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
    Heck MC; Wagner CE; Shahani PH; MacNeill M; Grozic A; Darwaiz T; Shimabuku M; Deans DG; Robinson NM; Salama SH; Ziller JW; Ma N; van der Vaart A; Marshall PA; Jurutka PW
    J Med Chem; 2016 Oct; 59(19):8924-8940. PubMed ID: 27592633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).
    Takamatsu K; Takano A; Yakushiji N; Morohashi K; Morishita K; Matsuura N; Makishima M; Tai A; Sasaki K; Kakuta H
    ChemMedChem; 2008 May; 3(5):780-7. PubMed ID: 18297677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.
    Zhang H; Li L; Chen L; Hu L; Jiang H; Shen X
    J Mol Biol; 2011 Mar; 407(1):13-20. PubMed ID: 21262235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes.
    Howell SR; Shirley MA; Ulm EH
    Drug Metab Dispos; 1998 Mar; 26(3):234-9. PubMed ID: 9492386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative retinoid X receptor (RXR) ligands.
    Krężel W; Rühl R; de Lera AR
    Mol Cell Endocrinol; 2019 Jul; 491():110436. PubMed ID: 31026478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-controlled competition of RAR and VDR nuclear receptors for heterodimerization with RXR is manifested in their DNA binding.
    Rehó B; Fadel L; Brazda P; Benziane A; Hegedüs É; Sen P; Gadella TWJ; Tóth K; Nagy L; Vámosi G
    J Biol Chem; 2023 Feb; 299(2):102896. PubMed ID: 36639026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.
    Yamada S; Kawasaki M; Fujihara M; Watanabe M; Takamura Y; Takioku M; Nishioka H; Takeuchi Y; Makishima M; Motoyama T; Ito S; Tokiwa H; Nakano S; Kakuta H
    J Med Chem; 2019 Oct; 62(19):8809-8818. PubMed ID: 31483660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.
    Nahoum V; Pérez E; Germain P; Rodríguez-Barrios F; Manzo F; Kammerer S; Lemaire G; Hirsch O; Royer CA; Gronemeyer H; de Lera AR; Bourguet W
    Proc Natl Acad Sci U S A; 2007 Oct; 104(44):17323-8. PubMed ID: 17947383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights.
    Sato Y; Ramalanjaona N; Huet T; Potier N; Osz J; Antony P; Peluso-Iltis C; Poussin-Courmontagne P; Ennifar E; Mély Y; Dejaegere A; Moras D; Rochel N
    PLoS One; 2010 Nov; 5(11):e15119. PubMed ID: 21152046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.
    Boerma LJ; Xia G; Qui C; Cox BD; Chalmers MJ; Smith CD; Lobo-Ruppert S; Griffin PR; Muccio DD; Renfrow MB
    J Biol Chem; 2014 Jan; 289(2):814-26. PubMed ID: 24187139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.